Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Clinical Programs
    • IRAK1/4
    • RIPK1
    • Partnered Programs
    • Clinical Trials
    • Investigator Sponsored Research
    • Expanded Access Policy
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
Nov 09, 2021 7:30am EST

Rigel to Participate in Two Upcoming Investor Conferences

Nov 02, 2021 4:01pm EDT

Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update

Oct 26, 2021 7:30am EDT

Rigel Announces Conference Call and Webcast to Report Third Quarter 2021 Financial Results and Business Update

Sep 28, 2021 4:00pm EDT

Grifols begins commercializing TAVLESSE® in France, Italy and Spain to treat chronic immune thrombocytopenia

Sep 02, 2021 7:30am EDT

Rigel to Participate in Three Upcoming Investor Conferences

Sep 01, 2021 7:30am EDT

Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases

Aug 13, 2021 7:30am EDT

Rigel Pharmaceuticals Provides Update on COVID-19 Program

Aug 03, 2021 4:01pm EDT

Rigel Reports Second Quarter 2021 Financial Results and Provides Business Update

Jul 27, 2021 7:30am EDT

Rigel Announces Conference Call and Webcast to Report Second Quarter 2021 Financial Results and Business Update

Jul 14, 2021 7:30am EDT

New TAVALISSE® Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress

  • Previous
  • 1…
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • …42
  • Next
RSS
Terms of Use Privacy Policy Your Cookie Preferences

© 2025 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, REZLIDHIA, GAVRETO, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

Facebook X Linkedin